These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 28185291)

  • 1. Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis.
    Kumar S; Singh J; Rattan S; DiMarino AJ; Cohen S; Jimenez SA
    Aliment Pharmacol Ther; 2017 Apr; 45(7):883-898. PubMed ID: 28185291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature.
    Jaovisidha K; Csuka ME; Almagro UA; Soergel KH
    Semin Arthritis Rheum; 2005 Feb; 34(4):689-702. PubMed ID: 15692963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of patients with early systemic sclerosis and severe gastrointestinal tract involvement.
    Nishimagi E; Tochimoto A; Kawaguchi Y; Satoh T; Kuwana M; Takagi K; Ichida H; Kanno T; Soejima M; Baba S; Kamatani N; Hara M
    J Rheumatol; 2007 Oct; 34(10):2050-5. PubMed ID: 17924608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility.
    Kawaguchi Y; Nakamura Y; Matsumoto I; Nishimagi E; Satoh T; Kuwana M; Sumida T; Hara M
    Ann Rheum Dis; 2009 May; 68(5):710-4. PubMed ID: 18762475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal and Hepatic Disease in Systemic Sclerosis.
    Frech TM; Mar D
    Rheum Dis Clin North Am; 2018 Feb; 44(1):15-28. PubMed ID: 29149923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation and management of gastrointestinal manifestations in scleroderma.
    Kirby DF; Chatterjee S
    Curr Opin Rheumatol; 2014 Nov; 26(6):621-9. PubMed ID: 25207461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
    Yoshizaki A
    Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis.
    Zekovic A; Damjanov N
    Rheumatol Int; 2017 May; 37(5):735-741. PubMed ID: 28271157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis.
    Zampatti N; Garaiman A; Jordan S; Dobrota R; Becker MO; Maurer B; Distler O; Mihai C
    Arthritis Res Ther; 2021 Apr; 23(1):125. PubMed ID: 33888149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early inflammatory players in cutanous fibrosis.
    Raker V; Haub J; Stojanovic A; Cerwenka A; Schuppan D; Steinbrink K
    J Dermatol Sci; 2017 Sep; 87(3):228-235. PubMed ID: 28655471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Khanna D; Hays RD; Maranian P; Seibold JR; Impens A; Mayes MD; Clements PJ; Getzug T; Fathi N; Bechtel A; Furst DE
    Arthritis Rheum; 2009 Sep; 61(9):1257-63. PubMed ID: 19714600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gastrointestinal features in systemic sclerosis].
    Stelle M; Chizzolini C
    Rev Med Suisse; 2014 Apr; 10(426):860-3. PubMed ID: 24834644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation.
    Luebker S; Frech TM; Assassi S; Gordon JK; Bernstein EJ; Steen VD; Shah AA; Hummers LK; Richardson C; Khanna D; Castelino FV; Chung L; Hant FN; Shanmugam VK; VanBuren JM; Alvey J; Harding M; Sandorfi N
    Clin Exp Rheumatol; 2023 Aug; 41(8):1632-1638. PubMed ID: 37497718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment.
    Volkmann ER; McMahan Z
    Curr Opin Rheumatol; 2022 Nov; 34(6):328-336. PubMed ID: 35993874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reliability, validity, and sensitivity of the Japanese version of the University of California Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument: Application to efficacy assessment of intravenous immunoglobulin administration.
    Matsuda KM; Sugimoto E; Ako Y; Kitamura M; Miyahara M; Kotani H; Norimatsu Y; Hisamoto T; Kuzumi A; Fukasawa T; Sato S; Yoshizaki A
    J Dermatol; 2024 Jun; 51(6):741-751. PubMed ID: 38558171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy.
    Henry TW; Mendoza FA; Jimenez SA
    Autoimmun Rev; 2019 Nov; 18(11):102396. PubMed ID: 31520794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention.
    Frech TM; Khanna D; Maranian P; Frech EJ; Sawitzke AD; Murtaugh MA
    Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S22-5. PubMed ID: 21586214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring response in the gastrointestinal tract in systemic sclerosis.
    Khanna D; Nagaraja V; Gladue H; Chey W; Pimentel M; Frech T
    Curr Opin Rheumatol; 2013 Nov; 25(6):700-6. PubMed ID: 24047604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis.
    Jerjen R; Nikpour M; Krieg T; Denton CP; Saracino AM
    J Am Acad Dermatol; 2022 Nov; 87(5):937-954. PubMed ID: 35131402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.